Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study.
Anisha B DuaKerri FordStefano FioreDimitrios A PappasJud C JanakTaylor BlachleyCarla Roberts-TolerKelechi EmeanuruJoel M KremerAlan J KivitzPublished in: Rheumatology and therapy (2023)
Patients with RA can achieve improvement in response when switching between IL-6Ri and JAKi. Although both therapies affect the IL-6 pathway, there are distinct mechanisms of action, which likely contribute to their clinical improvement, when reciprocally switched as follow-on treatments.